Avalo Therapeutics, Inc. Annual Report - How They Did This Year

Hey there! Thinking about Avalo Therapeutics, Inc. as an investment? Let's break down their past year. We'll cover what they do, their money situation, and big events. This will give you a good feel for the company.

Here's what we'll cover:

1. What does this company do and how did they perform this year? Avalo Therapeutics is a biotech company developing new drugs. They focus on immune-mediated inflammatory diseases. Their treatments use IL-1β, a protein known to cause inflammation. This past year, their main focus was abdakibart (AVTX-009). This is a special antibody that blocks IL-1β.

   AVTX-009 is in a Phase 2 clinical trial, called LOTUS. This trial targets hidradenitis suppurativa (HS), a painful skin condition. They finished enrolling patients in October 2025. Main results should come in mid-2026. If results are good, they plan larger Phase 3 trials.

   Avalo once had more drugs in development. They decided not to develop these 'legacy' programs internally. Instead, they seek partners to license or sell these drugs. This narrows their focus. Their future success now mostly depends on AVTX-009.

   HS affects about 3.4 million people in the US. This number will grow to 3.5 million by 2035. Millions more worldwide have HS. Patients need better treatments. Current options often don't help enough. The HS treatment market could exceed $10 billion by 2035. This makes it a lucrative area if AVTX-009 succeeds.

   Avalo protects its ideas with patents, trade secrets, and confidentiality agreements. As a biologics company, they also use regulatory protections. US law grants 12 years of data exclusivity for biologics. This protects their market even without patents.

   Avalo trades on the Nasdaq Capital Market (AVTX). This market is for smaller companies. It often means higher stock volatility and risk.

2. Financial performance - money coming in, profit, growth This is where things get really interesting, and a bit unusual. This information is for their year ending December 31, 2025.

   • Money Coming In: The company had no product sales in 2024 or 2025. This is normal for a biotech without a drug on the market. However, they also earned no money from partnerships or other operations. This is less common for a company with existing deals. They earned no income from sales or partner payments.

   • Costs: Even more unusual, they reported $0 for Research & Development (R&D) and general business costs in 2024 and 2025. This is unheard of for a company running a Phase 2 trial. It suggests a very unusual operating model. This could mean they outsource everything. Or, they mostly hold intellectual property, with few internal operations. This lean model creates big risks. They lack direct control over key work.

   • Growth: Normal growth measures like sales growth or profit don't apply here. For Avalo, growth means AVTX-009's clinical progress. It also means hitting milestones that trigger future payments. These payments could come from partners for their older drugs.

   • Future Payments Due: They reported $0 in money coming in and costs for 2024 and 2025. But their partnerships and acquisitions bring big future payment obligations. These show the high cost of developing AVTX-009. These costs are not in their reported R&D. For instance, if AVTX-009 succeeds, Avalo will owe Eli Lilly up to $70 million in development payments. They also owe up to $650 million based on sales. Plus, Lilly gets 5-15% of net sales. They also owe Leap Therapeutics up to $70 million for another drug's sales. These are huge future costs. Avalo will need to raise more money or sell drugs to pay them.

3. Major wins and challenges this year

   Wins:

   • Getting AVTX-009 from Lilly: In March 2024, Avalo licensed AVTX-009 from Eli Lilly. They gained global rights to develop and sell it. This was a big strategic step. It added a promising, late-stage drug to Avalo's lineup. Avalo pays for development and sales. But it shows Lilly believes in the drug. It gives Avalo a clear main drug.
   • Buying Almata Bio and Milestones: Also in March 2024, Avalo bought Almata Bio. Almata Bio originally developed AVTX-009. This secured full rights to the drug for Avalo. Avalo paid $7.5 million upfront to Almata Bio's previous owners. In October 2024, they dosed the first patient in the Phase 2 HS trial. This triggered a $5.0 million payment to Almata Bio's former owners. Another $15.0 million is due if AVTX-009 enters Phase 3 trials. This shows their commitment to the drug.
   • Phase 2 Enrollment Finished: They finished enrolling patients for the AVTX-009 Phase 2 LOTUS trial in October 2025. This keeps them on track for main results in mid-2026.
   • New Patents for AVTX-009: AVTX-009's main patent expired in February 2026. But Avalo filed new patents for treating HS with the drug. They also filed patents for its formulations. If granted, these patents could protect the drug until 2045. This helps reduce risk from the expired patent. It could extend market exclusivity beyond regulatory data protection.
   • Ongoing Partnerships to License Out Drugs: Avalo manages active license deals for other drugs. These include AVTX-002 with Kyowa Kirin, AVTX-006 with Astellas, AVTX-301 with Alto, and AVTX-406 with ES Therapeutics. Avalo receives payments and royalties if these programs advance. These could be future income streams, separate from AVTX-009.

   Challenges:

   • No Money Coming In: No product sales or partnership money is a big problem. Avalo earns no income from its drugs or licensed assets.
   • Very Lean Operations: Reporting $0 for R&D and general costs is very unusual for a biotech. It's concerning. This might mean extreme efficiency or outsourcing. But it also suggests minimal internal staff. This is a big risk if partnerships fail. Or if they need to quickly grow internal work.
   • Selling Assets & Narrowed Drug Focus: Avalo sold its AVTX-800 series drugs in October 2023. They recently decided not to develop other drugs (AVTX-002, AVTX-006, AVTX-008, AVTX-913). Instead, they seek 'strategic alternatives' for them. This greatly narrows their focus. Avalo now relies heavily on AVTX-009's success. This increases their risk.
   • Big Future Payments Due: Avalo owes Lilly up to $70M for development and $650M for sales milestones. Plus, 5-15% royalties. They also owe Leap Therapeutics up to $70M for sales milestones. Another $15.0M is due for the Almata Bio purchase if AVTX-009 enters Phase 3. These are huge financial commitments. They will need a lot of money to pay them.
   • Relies on One Manufacturer: Avalo uses one outside company to make AVTX-009 for trials. This is a big risk. Problems with this manufacturer could delay trials. Quality issues, capacity limits, or supply disruptions are risks. This could also delay future sales.
   • Limited Sales & Marketing: Avalo is a development-stage company. They have very limited sales, distribution, or marketing staff. If AVTX-009 gets approved, they must invest heavily to build this team. Or, they need good sales partners. This is complex, costly, and takes time.

4. Financial health - cash, debt, ability to pay bills This is another area with some very concerning figures from the filing for the year ending December 31, 2025:

   • Cash: The company reported $0 cash and no short-term investments. This was true for both 2024 and 2025. This is extremely alarming for any company. It means Avalo is in a very risky financial state. Its survival depends on constantly raising new money. No cash means immediate money problems. They cannot fund basic operations. They also can't fund trials or future payments. They need constant outside money.
   • Market Value: As of June 30, 2025, the total stock value available to regular investors was about $53.7 million. This shows the company's small size in the market.
   • Raising Money: Despite having no cash, Avalo actively raises money to operate. They do this through 'private placements.' This means selling preferred stock and warrants to private investors. They also use an 'At-the-Market' (ATM) program. This sells new shares to the public over time. This constant need for money means they spend cash fast. They must keep finding ways to fund operations. This can mean more shares issued, reducing your ownership percentage.
   • Outstanding Shares: As of March 18, 2026, they had 22,788,452 common shares outstanding. This number matters when new shares are issued. It impacts potential dilution.
   • Complex Debts: The company also has 'derivative liabilities' and warrants. These are complex financial tools, often from financing deals. Their value can change a lot. This depends on the stock price or market conditions. They add more financial risk. This makes Avalo's finances harder for investors to understand. It could lead to unexpected costs or more shares issued, reducing your ownership percentage.
   • Ongoing Losses: Avalo has lost money since it started. They expect this to continue. They are not profitable. They constantly spend cash to fund drug development.

5. Key risks that could hurt the stock price

   • No Money Coming In: With no product sales or partnership money, Avalo relies entirely on raising money. Long-term, it depends on AVTX-009's success. Or, on uncertain payments from partners for older licensed drugs.
   • Extreme Financial Risk: The reported $0 cash, R&D, and general costs suggest a very lean or non-operational internal structure. This makes them very vulnerable to problems. It raises doubts about their ability to keep operating. They need constant, successful fundraising.
   • Shareholder Dilution: New shares are constantly issued. This increases total shares. It can reduce the value of each existing share. It also means more shares issued, reducing your ownership percentage.
   • Heavy Reliance on Partnerships & Outside Companies: Avalo's future depends heavily on its partners' success. This includes partners for licensed-out drugs. It also depends on how they manage AVTX-009. They also rely heavily on outside companies for manufacturing and trials. If partners or third parties fail, drop a program, or Avalo breaks a deal, it could severely hurt the company. This affects its operations and financial health.
   • Clinical Trial Risks: Most of Avalo's drugs, especially AVTX-009, are still in early or mid-development. Clinical trials are risky. AVTX-009 might not be safe or effective. Trial failures, delays, or bad results could cost Avalo more. They might never get drugs to market. This would severely hurt the company's value.
   • Regulatory Hurdles: Even if clinical trials go well, getting FDA approval is long, costly, and unpredictable. AVTX-009 might not get approved. Or, it could be for a narrower use. It might also have costly post-approval rules.
   • Intellectual Property & Market Exclusivity for AVTX-009 (Updated): This is complex but very important. The main US patent for AVTX-009 expired in February 2026. This is a big worry. If approved, other companies could sell generic versions sooner. This would limit Avalo's exclusive sales. As a biologic, AVTX-009 could get 12 years of US regulatory exclusivity if approved. Europe might offer 9-11 years. This starts from FDA approval. This means generic versions (biosimilars) cannot enter the market then. This is true even without a patent. Avalo also filed new patents for AVTX-009. These cover treating HS and its formulations. If granted, they could protect the drug until 2045. The risk is that these protections might not be as strong. A long-standing main patent would be better. Regulatory exclusivity can also face changes or legal challenges.
   • Heavy Focus on AVTX-009: A big risk: Avalo focuses almost all resources on AVTX-009. They stopped other older drug programs. If AVTX-009 fails or faces big problems, it could devastate the company. This focus means they might waste limited resources on AVTX-009. They could also miss other good chances.
   • Manufacturing Dependence: Using just one outside company to make AVTX-009 is a big risk. Problems with this manufacturer could severely impact trials. Production delays, quality issues, or regulatory problems are risks. This could also affect market supply if approved.
   • Sales Challenges: Avalo has limited sales and marketing staff. If AVTX-009 gets approved, they must invest heavily to build this team. Or, they need good sales partners. This is hard, costly, and success is not guaranteed against competitors.
   • Intense Competition: The market for inflammatory diseases, especially HS, is very competitive. Avalo faces big drug companies like AbbVie, Lilly, and Novartis. These companies have far more money, R&D, manufacturing, and sales experience. Approved HS treatments exist (TNF alpha and IL-17 inhibitors). Many other companies develop similar or different drugs. Several are in late-stage (Phase 3) HS trials. AVTX-009 will face a crowded, well-funded field. Gaining market share will be hard, even if approved.
   • Complex Financial Tools: Derivative liabilities and warrants make Avalo's finances complex. They add potential volatility. These are hard to value. They might lead to unexpected accounting costs. They can also mean more shares issued, reducing your ownership percentage.
   • Market Acceptance Risk: Even if AVTX-009 is approved, doctors and patients might not widely use it. This would limit sales. It would also hurt Avalo's ability to make a profit.
   • Key Personnel Risk: Losing key staff could severely hurt their drug development. It could also hinder their business plan. This is especially true given their lean operations.
   • Ongoing Losses: Avalo has consistently lost money since it started. They expect this to continue. They are not profitable. They will keep needing outside funding.
   • Stock Price Volatility: Their stock price can swing wildly. This happens sometimes for reasons unrelated to company performance. This makes its true value hard to judge. It can expose investors to big risks.

6. Competitive positioning The HS market is large and growing. It could exceed $10 billion globally by 2035. Approved HS biologics exist, like adalimumab (TNF alpha inhibitor) and secukinumab/bimekizumab (IL-17 inhibitors). But there's still a big unmet need. Current treatments often don't work well enough. For example, only about 50% of patients reach HiSCR50. Higher response rates are even lower. This means a more effective or tolerable drug like AVTX-009 could succeed. But it must perform well in trials.

   However, competition is intense. Novartis and GenSci already have two approved anti-IL-1β antibodies. Avalo is one of three companies developing new, non-biosimilar anti-IL-1β antibodies. The wider HS market includes many big drug companies. AbbVie, Lilly, Novartis, and UCB have approved TNF alpha and IL-17 inhibitors. At least six other companies have late-stage (Phase 3) HS drugs. These use various methods, like other IL-17, JAK, BTK, and dual IL-1α/β inhibitors. Many competitors have far more money and experience. They have better R&D, manufacturing, and sales teams. AVTX-009 will face a crowded, well-funded field. Gaining market share will be hard, even if approved.

   Larger companies like Lilly licensed their drugs to Avalo. This suggests they see the scientific value of these compounds. An 'asset-light' model works for small biotechs. They license drugs to bigger players for later development and sales. But for AVTX-009, Avalo handles development and sales itself. They must build a big sales and marketing team. Or, they need good sales partners to compete well.

So, what does this all mean for you? Avalo Therapeutics, Inc. presents a high-risk, high-reward investment. Its future hinges almost entirely on AVTX-009's success in trials and its ability to secure ongoing funding. Weigh these factors carefully as you consider your investment options.